| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF9 |
| Uniprot No | Q07011 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-186aa |
| 氨基酸序列 | LQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFR TRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFG TFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPADLSPGASSVT PPAPAREPGHSPQ |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF9(CD137/4-1BB)重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**: *"Structural and functional characterization of recombinant human 4-1BB ligand"*
**作者**: Hurtado JC, et al.
**摘要**: 该研究通过重组表达技术制备了人源4-1BB配体(CD137L)，并解析了其与TNFRSF9受体结合的晶体结构。实验表明，重组CD137L通过激活TNFRSF9可显著增强T细胞的增殖和细胞因子分泌，为免疫治疗提供了结构基础。
2. **文献名称**: *"Agonistic anti-CD137 antibodies in cancer immunotherapy: Current status and future directions"*
**作者**: Chester C, et al.
**摘要**: 文章综述了靶向TNFRSF9的激动性抗体及重组蛋白在肿瘤免疫治疗中的作用机制，总结了其通过激活T细胞和NK细胞抗肿瘤活性的临床前及临床试验结果，并讨论了其联合用药的潜力。
3. **文献名称**: *"Recombinant soluble CD137 protein inhibits angiogenesis by blocking VEGF-mediated signaling"*
**作者**: Wang Q, et al.
**摘要**: 研究发现，可溶性重组TNFRSF9蛋白能通过竞争性结合血管内皮生长因子(VEGF)受体，抑制肿瘤微环境中血管生成相关信号通路，从而在体内模型中显著减少肿瘤生长和转移。
---
以上文献涵盖了TNFRSF9重组蛋白的结构解析、免疫治疗应用及抗血管生成机制，反映了其多方面的研究价值。如需具体文献来源或补充，可进一步提供研究方向或数据库筛选条件。
TNFRSF9. also known as CD137 or 4-1BB, is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a critical role in regulating immune responses. It is a type I transmembrane protein expressed on activated T cells, natural killer (NK) cells, dendritic cells, and other immune cells. TNFRSF9 functions as a costimulatory receptor, enhancing T cell proliferation, survival, and cytokine production upon binding to its ligand, 4-1BBL. This interaction activates downstream signaling pathways, including NF-κB and MAPK, which promote immune cell activation and antitumor immunity.
Recombinant TNFRSF9 protein is typically engineered as a soluble form, often fused with Fc domains (e.g., human IgG1 Fc) to improve stability and bioavailability. It is widely used in research to study immune modulation, particularly in cancer immunotherapy. By mimicking natural receptor-ligand interactions, recombinant TNFRSF9 can either agonize or block signaling pathways, making it a valuable tool for exploring therapeutic strategies. For instance, agonist antibodies or recombinant proteins targeting TNFRSF9 have shown potential in boosting T cell responses in combination with CAR-T therapies or immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1).
In disease models, TNFRSF9 activation has been linked to enhanced antitumor efficacy but also to risks of autoimmune or inflammatory side effects, highlighting its dual role. Researchers utilize recombinant TNFRSF9 to dissect these mechanisms, optimize dosing, and develop targeted therapies. Its applications extend to infectious diseases and vaccine adjuvants, where amplifying T cell immunity is critical. Overall, TNFRSF9 recombinant protein serves as a pivotal reagent in both basic immunology and translational studies aimed at harnessing costimulatory pathways for therapeutic benefit.
×
